QSE 6 — Documents and Records
6.0 Documents and Records
The organization shall ensure that documents and records are created, stored, and archived in accordance with record retention policies.
This standard sets forth requirements for two separate types of written or electronically captured materials: documents and records. Because the integrity of a quality system is dependent on its documents and records, a whole section of the CT Standards is dedicated to ensuring that the program has processes and procedures for controlling its documents. These CT Standards draw a distinction between documents and records; the glossary provides definitions. Records should be created concurrently and be attributable, legible, contemporaneous, original, accurate, and complete. These records should be stored in a manner that protects their integrity for a defined period that meets or exceeds the requirements of these CT Standards or the applicable regulatory authority. (SS)
6.1 Document Control
The organization shall control all documents that relate to the requirements of these CT Standards. Documents shall be protected from unauthorized access and accidental or unauthorized modification, deletion, or destruction.
Standard 6.1 Document Control, is a commonly cited standard for nonconformances. Examples of the reasoning behind the nonconformances include the following:
- Policies, processes, and procedures for document control are not being followed.
- Outdated SOPs or forms are in use when they have been revised.
- Uncontrolled documents are found in use.
- Documents are not reviewed or approved before use. (SS)
The committee revised standard 6.1 based on updates to the AABB Quality System Essentials. (SC)
6.1.1 Format
Documents shall be in standardized formats. Additional policies, processes, and procedures (such as those in an operator’s manual or published in the AABB Technical Manual) may be incorporated by reference.
To promote ease of use, all documents that are created by the facility are required to be in a standardized format, although other external documents may be incorporated by reference. The documents should include the purpose, materials, and equipment needed, and identified endpoints. Additional procedures developed by manufacturers or other facilities (such as those found in an operator’s manual or the AABB Technical Manual) may be incorporated by reference and need not be in the standardized format. Where procedures developed by manufacturers are incorporated by reference, the reference must include the insert or manual version number and which procedure is referenced, if there is more than one. Incorporation by reference is intended for unmodified procedures. Modified procedures must be incorporated into the laboratory’s own documentation. (SS)
The committee revised standard 6.1.1 based on updates to the AABB Quality System Essentials. (SC)
6.1.2 Document Review, Approval, and Distribution
[Cord blood applicable]
The document control process shall ensure that documents:
- Are reviewed by personnel trained and/or qualified in the subject area.
- Are approved by an authorized individual.
- Are identified with the current version and effective date.
- Are available at all locations where operations covered by these CT Standards are performed.
- Are not used when deemed invalid or obsolete.
- Are identified as archived or obsolete when appropriate.
6.1.3 Document Changes
[Cord blood applicable]
Changes to documents shall be reviewed and approved by an authorized individual.
The committee revised standard 6.1.3 based on updates to the AABB Quality System Essentials. (SC)
6.1.3.1
The organization shall track changes to documents.
6.1.4 Master List of Documents
[Cord blood applicable]
The organization shall maintain complete lists of all active policies, processes, procedures, labels, forms, and other documents that relate to the requirements of these CT Standards.
All facilities are required to maintain a master list of current policies, processes, procedures, and forms. The master list may be in printed or electronic format. It is recommended that a master list include the following information: title of document, holder (owner or person responsible) of document, current revision number, and date of implementation. It is acceptable for separate departments within a facility to control documents differently; however, there should be a system that links them. An example of a master list is a table of contents for a quality manual. The master list will be an effective tool in preventing obsolete documents from being used. It may also be helpful to new employees in locating a specific document.
Facilities may organize a master list by linking a policy with related processes, related procedures, and related forms. Alternatively, there may be a comprehensive list of all policies, another list of processes, a list of procedures, and a list of forms.
It is not necessary to maintain a master manual of the text of all policies, processes, and procedures. It is important to identify the individuals who control the master list. Often, the individual departments control the master list. For example, the department director’s assistant might control the master list on their computer. The intent is to indicate that it is acceptable to have multiple master lists as long as the document control system is defined in the processes and procedures. Regardless of who controls the master list, executive management should always have a list of all departmental master lists or access to all departmental master lists. In some instances, departments include the master lists of other departments in their manuals so that staff can see whether a process or procedure already exists in another department. (SS)
6.1.5 Review of Policies, Processes, and Procedures
[Cord blood applicable]
Review of each policy, process, and procedure shall be performed by an authorized individual at a minimum of every 2 years.
Before implementation, it is required that all documents relating to the requirements of the quality system and the CT Standards be reviewed and approved by authorized individuals.
Document control requires that documents be changed or corrected in the same manner in which they are created. When revisions to existing documents are submitted for approval, those making decisions should have the appropriate information to make the decision. Once changes to documents are made, personnel have to be trained on the new processes or procedures.
Each program should identify who will:
- Review the documents and how they will be reviewed, including manner and scope.
- Define what level of authority will approve the final documents.
The same person may perform both functions. Written documentation of the medical director’s or designee’s review is required. This could be accomplished by initials and date of review for policies. Processes and procedures can be documented by a flow chart, and annual review can be documented by initials and date of review. Electronic documentation of directorial review is also acceptable. (SS)
6.1.6 Document Retention
[Cord blood applicable]
The organization shall determine which documents shall be archived, destroyed, or made obsolete.
6.1.7 Document Storage
Documents shall be stored in a manner that preserves integrity and legibility; protects from accidental or unauthorized access, loss, destruction, or modification; and ensures accessibility and retrievability.
6.1.8 Document Retrieval
The organization shall ensure that documents are retrievable in a timely manner.
6.1.9
The organization shall use only current and valid documents. Applicable documents shall be available at all locations where activities essential to meeting the requirements of these CT Standards are performed.
The committee added standard 6.1.9 based on updates to the AABB Quality System Essentials. (SC)
6.2 Record Control
The organization shall maintain a system for identification, collection, indexing, accessing, filing, storage, maintenance, and disposition of original records.
A record is information (captured in writing or in an electronically generated medium) that provides
objective evidence of activities that have been performed or results that have been achieved, such as test records or assessment results. Records do not exist until the activity has been performed and documented.
Records prove that:
- A product or service conforms to specified requirements.
- Each step of the quality system is being performed.
Records may be maintained in writing or an electronically generated format; however, their security has to be ensured. (SS)
The committee revised standard 6.2 based on updates to the AABB Quality System Essentials. (SC)
6.2.1 Records
Records shall be complete, retrievable in a period appropriate to the circumstances, and protected from accidental or unauthorized destruction or modification.
The committee added standard 6.2.1 based on updates to the AABB Quality System Essentials. (SC)
6.2.2 Record Traceability
The records system shall ensure traceability of:
- Critical activities performed.
- The individual who performed the activity.
- Date the activity was performed.
- Time the activity was performed, if applicable.
- Results obtained.
- Method(s) used.
- Equipment used.
- Critical materials used.
- The organization where the activity was performed.
Facilities that collect cellular therapy products by apheresis that are for further manufacturing by a clinical trial sponsor or manufacturer should ensure that they maintain a chain of custody that includes concurrent, permanent, auditable documentation illustrating the guardianship of the cell (or gene) therapy product. (SS)
6.2.3 Information to Be Retained
Records shall demonstrate that a material, product, or service conforms to specified requirements and that the quality system is operating effectively.
6.2.3.1
Records from suppliers shall be an element of this information.
6.2.4 Legibility
All records shall be legible and indelible.
6.2.5 Record Change
[Cord blood applicable]
The organization shall establish processes for changing records. The date and identity of the person making the change shall be recorded. Record changes shall not obscure previously recorded information.
Unauthorized changes to records must not be allowed. For this reason, all changes to records must be controlled and traceable. The intent of this standard is to be sure that the original information recorded, which would be the information that was concurrently recorded as required in Standard 6.2.6, is still readable after changes are made. For a variety of reasons, including the possible need to track and trend changes made to records for process improvements, it is also important to be able to understand why changes were made to a record, who made the change, and when it was made. (SS)
6.2.5.1
Changes to records (including electronic records) shall be verified for accuracy and completeness.
The committee added standard 6.2.5.1 based on updates to the AABB Quality System Essentials. (SC)
6.2.5.2
Modifications or changes that can affect the safety of the recipient or quality of the cellular therapy product shall be approved by the authorized individual. Chain of identity shall be maintained.
Unauthorized changes to records must not be allowed. For this reason, all changes to records must be controlled and traceable. The intent of this standard is to be sure that the original information recorded, which would be the information that was concurrently recorded as required in Standard 6.2.6, is still readable after changes are made. For a variety of reasons, including the possible need to track and trend changes made to records for process improvements, it is also important to be able to understand why changes were made to a record, who made the change, when it was made, and, per Standard 6.2.5.2, who authorized the change if the change impacts product quality or recipient safety. It is also important that changes do not adversely impact the traceability of product identity. (SS)
6.2.5.3
The actual result of each action performed shall be recorded immediately, and the final interpretation shall be recorded upon completion of testing.
Unauthorized changes to records must not be allowed. For this reason, all changes to records must be controlled and traceable. The intent of this standard is to be sure that the original information recorded, which would be the information that was concurrently recorded as required in Standard 6.2.6, is still readable after changes are made. For a variety of reasons, including the possible need to track and trend changes made to records for process improvements, it is also important to be able to understand why changes were made to a record, who made the change, and when it was made. (SS)
6.2.6
Records shall be created concurrently with the performance of each critical activity.
The intent of this standard is to be sure that information is recorded in the most accurate way, before distractions and the passage of time interfere with the best possible recording of information. (SS)
6.2.6.1
The record shall identify the work performed, the individual performing the activity, and when it was performed.
6.2.7 Copies
[Cord blood applicable]
Before destruction of original records, copies of records shall be verified as containing the original content and shall be legible, complete, and accessible.
The responsibility for each program is to determine what the “official” record is. Some programs prefer to use paper copies as the official record. This practice is acceptable as long as it is defined in the program’s processes and procedures. In this instance, worksheets serve as the official record. Later, if there are questions about the results, employees would know to refer to the information on the worksheet. These worksheets are subject to record retention requirements.
At other programs, the computer record serves as the official record. This practice is also acceptable as long as it is defined in the facility’s processes and procedures. In this case, employees enter data straight into the computer and no paper is used. In other programs, the paper worksheets serve as the official copy, although the information is still entered into a computer system and is used by billing departments or as patient records. Issues to keep in mind when computer records serve as the official records are: security of the computer system, traceability of changes, functionality of the backup system, protection against document adulteration, and proper record retention.
An original record might be destroyed when information from worksheets is entered into a computer. Before it is destroyed, however, the program must ensure that all necessary information on the record is accurately transferred to an alternate source (eg, the computer system). Because the worksheet is the original record, verification of accurate transfer of the information is required before any “source” documentation is destroyed. The program should consider how it will verify that information has been transferred accurately.
Another instance when records may be destroyed is when copies of original records are stored on storage media, such as microfiche and videodisc, or scanned into a portable document format (pdf) file. Because these storage media are exact copies of original records, the original records could be destroyed and the microfiche/videodiscs or computer files retained according to record retention requirements. Depending on the storage media used, it is important to retain the appropriate technology to ensure a method to read the records in the future. In some cases, this might include retaining a particular software program that would allow reading of the stored document files.
The standard requires that the program verify that copies of records contain all of the original content, and in order to meet the standard, verification is documented as a record. Vendor qualification may be one method of satisfying this requirement. During agreement review with the storage media company, the facility can require that the vendor state how it will verify that complete and appropriate records are transferred to the other storage media.
In all cases, the official records have to be maintained for the appropriate length of time in accordance with specified requirements, including record retention requirements, and state and local laws, when applicable. (SS)
6.2.8 Confidentiality
The organization shall ensure the confidentiality of records.
The facility should have policies, procedures, and processes to ensure the security and privacy of patient and employee data, and protection from inadvertent or hostile disclosure. These data include: name, address, date of birth, phone number, gender, ethnic group, diagnosis, prescriptions, medical records, billing, and tax identifier. (SS)
The committee revised standard 6.2.8 based on updates to the AABB Quality System Essentials. (SC)
6.2.9 Retention
Records required by these CT Standards shall be retained for a period indicated in the record retention table at the end of each chapter.
6.2.9.1
These records shall be retained at least 10 years following either their creation (C) or the final disposition (F) of the cellular therapy product with which they are associated. Applicable FDA, or relevant Competent Authority, or local law may exceed this period.
6.2.9.1.1
If the date of administration is unknown, records shall be retained for 10 years after the date of distribution, disposition, or expiration, whichever is latest. Applicable FDA, or relevant Competent Authority, or local law may exceed this period.
If a product was distributed from one facility to another, and the date of administration is not reported to, or obtained by, the original distribution facility, then the length of record retention needs to be determined with the distribution facility, which would maintain product records for the latest date. For example, if a product was distributed on April 1, 2023 but is due to expire April 1, 2025, then the facility would retain the product records until 10 years after the expiration date of April 1, 2025. (SS)
6.2.10 Record Review
[Cord blood applicable]
Records shall be reviewed for accuracy, completeness, and compliance with applicable standards, laws, and regulations.
6.2.11 Storage of Records
Records shall be stored to:
- Preserve record legibility and integrity for the entire retention period.
- Protect from accidental or unauthorized access, loss, deterioration, damage, destruction, mix-up, or modification.
- Permit ready identification.
- Allow retrieval in a defined time frame.
6.2.12 Destruction of Records
Destruction of records shall be conducted in a manner that protects the confidential content of the records.
Because records might contain protected health information, destruction of records might need to be
accomplished in such a way as to ensure that all protected information is not inadvertently disclosed to unauthorized individuals. (SS)
6.3 Electronic Records
[Cord blood applicable]
The organization shall support the management of information systems.
The committee revised standard 6.3 based on updates to the AABB Quality System Essentials. (SC)
6.3.1 Access to Data and Information
Access to data and information shall be controlled.
6.3.1.1
The authorization to access and release data and information shall be defined, and individuals
authorized to enter, change, and release results shall be identified.
The committee revised standard 6.3.1.1 based on updates to the AABB Quality System Essentials. (SC)
6.3.1.1.1
[Cord blood applicable]
Electronic records shall include the date and identity of the person making a change.
6.3.1.2
Individuals shall be identified and defined by job description that are authorized to create,
modify, maintain, or transmit records in a controlled and approved manner in conformance with the FDA or relevant Competent Authority requirements.
6.3.2 Data Integrity
Data integrity shall ensure that data are retrievable and usable.*
6.3.2.1
Data shall be accurately, reliably, and securely sent from the point of entry to final destination.
The committee revised standard 6.3.2.1 based on updates to the AABB Quality System Essentials. (SC)
6.3.2.2
Data shall be retrievable for the entire retention period.
6.3.2.2.1
The organization shall archive records or data from media and platforms no longer in use.
The committee revised standard 6.3.2.2.1 based on updates to the AABB Quality System Essentials. (SC)
6.3.2.3
There shall be a process in place for routine backup of all critical data.
6.3.3 Storage Media
Data storage media shall be protected from damage or unintended access and destruction.
The committee revised standard 6.3.3 based on updates to the AABB Quality System Essentials. (SC)
6.3.4 Backup Data
The organization shall back up all critical data.
The committee revised standard 6.3.4 based on updates to the AABB Quality System Essentials. (SC)
6.3.4.1
Backup data shall be stored in a secure offsite location.
All facilities should have off-site storage for backup data. The facility should implement reasonable measures to mitigate against loss, maintain integrity, and ensure access to critical data elements.
Many facilities already have off-site storage for patient files, administrative files, and financial records. The use of similar storage facilities for products should be explored through the administrative group at the facility. Off-site storage could also be at a sister facility, if there is one, with each storing the other’s backup data. The off-site location should also meet all security requirements for the level of data being stored to prevent tampering or violation of requirements contained in the Health Insurance Portability and Accountability Act (HIPAA).
The off-site storage should meet the temperature and other environmental requirements for the media to be stored (eg, heat/cold/humidity, magnetic influences, and security). (SS)
6.3.4.2
Backup data shall be protected from unauthorized access, loss, or modification.
6.3.4.3
The ability to retrieve data from the backup system shall be tested at defined intervals.
Excerpt of Reference Standard 6.2.9A Relevant to Documents and Records
| Standard | Record to Be Maintained | Quality System Records | Donor Eligibility/Management issues | Unit/Recipient |
Retention after Creation (C) or Final Disposition (F) of Related Product |
Minimum Retention Time (in years)1 |
| 6.1.2 |
Document control, including review and approval of all documents before use |
X | X | X | C | 10 |
| 6.1.3 |
Review and approval of changes to documents |
X | X | X | C | 10 |
| 6.1.4 |
List of all active policies, processes, procedures, labels, and forms |
X | X | X | C | 10 |
| 6.1.5 |
Biennial review of each policy, process, or procedure |
X | X | X | C | 10 |
| 6.1.6 |
Documents that are archived, destroyed, or made obsolete |
X | X | X | C | 10 |
| 6.2.5 | Record change | X | X | X | C | 10 |
| 6.2.7 |
Verification that copies of records contain the original content and are legible, complete, and accessible before the original records are destroyed |
X | X | X | C | 10 |
| 6.2.10 |
Review of records for accuracy, completeness, and compliance with applicable standards, laws, and regulations |
X | X | X | C | 10 |
| 6.3 | Electronic records | X | X | X | C | 10 |
| 6.3.1.1.1 |
Date and identity of person making change(s) to electronic records |
X | X | X | C | 10 |
1Applicable federal, state, or local law may exceed this period.
Reference Standard 6.2.9A — Retention of Records
| Standard | Record to Be Maintained | Quality System Records | Donor Eligibility/Management Issues | Unit/Recipient |
Retention after Creation (C) or Final Disposition (F) of Related Product |
Minimum Retention Time (in years)1 |
| 1.1.3.1.2 |
Procurement medical director management or review of 10 cell procurement procedures |
X | X | X | C | 10 |
| 1.1.4.1.2 |
Laboratory medical director management or review of 10 cell product processing procedures |
X | X | X | C | 10 |
| 1.1.4.2.2 |
Laboratory director management or review of 10 cell product processing procedures |
X | X | X | C | 10 |
| 1.1.5.2.2 |
Relevant continuing education of the clinical program director |
X | X | X | C | 10 |
| 1.2.1.1.1, 1.2.1.1.2 |
Quarterly reports by quality representative to executive management |
X | X | X | C | 10 |
| 1.2.2 |
Management review of effectiveness of the quality system |
X | X | X | C | 10 |
| 1.2.2.1 | Yearly review of the quality system | X | X | X | C | 10 |
| 1.3 | Policies, processes, and procedures | X | X | X | C | 10 |
| 1.3.1.1 |
Procurement medical director review and approval of all medical policies, processes, and procedures |
X | X | X | C | 10 |
| 1.3.1.2 |
Laboratory medical director review and approval of all medical policies, processes, and procedures |
X | X | X | C | 10 |
| 1.3.1.3 |
Laboratory director review and approval of all technical policies, processes, and procedures |
X | X | X | C | 10 |
| 1.3.1.4 |
Clinical program director review and approval of all clinical policies, processes, and procedures |
X | X | X | C | 10 |
| 1.3.2 |
Exceptions to policies, processes, and procedures |
X | X | X | C | 10 |
| 1.4 | Risk assessment | X | X | X | C | 10 |
| 1.6.1 |
Emergency operation plan tested at defined intervals |
X | X | X | C |
2 years, or two organizational testing intervals (whichever is longer) |
| 2.1.1 | Job descriptions | X | X | X | C | 10 |
| 2.1.2 |
Qualification of personnel performing critical tasks |
X | X | X | C | 10 |
| 2.1.3 | Training records of personnel | X | X | X | C | 10 |
| 2.1.3.1 |
Identification of qualifications required for trainers |
X | X | X | C | 10 |
| 2.1.4 | Evaluations of competence | X | X | X | C | 10 |
| 2.1.4.1 |
Corrective action when competence has not been demonstrated |
X | X | X | C | 10 |
| 2.1.5 |
Personnel records of each employee |
X | X | X | C | 10 |
| 2.1.6, 2.1.6.1 | Continuing education requirements | X | X | X | C | 10 |
| 3.2 | Equipment qualification | X | X | X | C |
10 years after retirement of the equipment |
| 3.4 | Unique identification of equipment | X | X | X | C | 10 |
| 3.5.1 | Equipment calibration activities | X | X | X | C | 10 |
| 3.5.2 | Equipment found to be out of calibration | X | X | X | C | 10 |
| 3.5.3 |
Equipment monitoring, maintenance, calibration, and repair |
X | X | X | C | 10 |
| 3.6 | Equipment traceability | X | X | X | C | 10 |
| 3.7 |
Implementation and modification of software, hardware, or databases |
X | X | X | C |
2 years after retirement of system |
| 3.7.1 | Testing of alternative systems | X | X | X | F | 10 |
| 3.8 | Monitoring of technology infrastructure | X | X | X | F | 10 |
| 3.9 | Alarm system check | X | X | X | F | 10 |
| 4.1 |
Evaluation and participation in selection of suppliers |
X | X | X | C | 10 |
| 4.2 | Agreements | X | X | X | C | 10 |
| 4.2.1 | Agreement review | X | X | X | C | 10 |
| 4.2.3 |
Agreements concerning activities involving more than one organization |
X | X | X | C | 10 |
| 4.2.4 |
Agreement changes communicated to affected parties |
X | X | X | C | 10 |
| 4.2.5 |
Review of agreements before acceptance and at facilitydefined intervals |
X | X | X | C | 10 |
| 4.2.5.1 |
Agreements for the timing and responsibility of medical orders |
X | X | X | F | 10 |
| 4.3 |
Inspection of incoming critical materials |
X | X | X | C | 10 |
| 4.3.1 |
Agreements between departments or facilities regarding the transfer of products |
X | X | X | F | 10 |
| 4.3.2 |
Agreements for the collection, transport, receipt, handling, and administration of the cellular therapy product, reporting adverse events, and obtaining outcome data |
X | X | X | F | 10 |
| 4.3.3 |
Agreement between processing/ issuing facility and the administering facility or registry for creation and retention of records; agreements for each facility to access relevant records |
X | X | X | C | 10 |
| 4.3.4 |
Conditions for product storage and disposition |
X | X | X | C | 10 |
| 4.3.6 | Shipment of cellular therapy products | N/A | N/A | X | F | 10 |
| 4.4 |
Claims in educational and promotional materials |
X | X | X | F | 10 |
| 4.5 | Donor informed consent | X | X | X | F | 10 |
| 4.6 |
Authorization for cadaveric donors |
X | X | X | F | 10 |
| 4.7 | Patient informed consent | X | X | X | F | 10 |
| 4.8.1, 4.8.2 |
Evaluation, qualification, and selection of suppliers of materials, services, and products |
X | X | X | F | 10 |
| 4.8.3 |
Monitoring of suppliers (including reporting to management of a supplier’s failures to meet specified requirements) |
X | X | X | F | 10 |
| 4.8.4 |
Notification of shipping facility and manufacturer (if applicable) when materials are received in an unacceptable condition |
X | X | X | C | 10 |
| 5.1.1 |
Validation of new or changed processes and procedures |
X | X | X | C | 10 |
| 5.1.2 |
Quality control records and review of quality control results |
X | X | X | C | 10 |
| 5.1.8 |
Identification and traceability of products |
N/A | N/A | X | C | 10 |
| 5.1.9.1 |
Supplier and/or consignee processes for traceability, tracking, and recall of products |
X | X | X | C | 10 |
| 5.1.9.1.1 |
Facility policy for the use/issue of a cellular therapy product provided by a supplier and/or received by a consignee that lacks a complete chain of custody |
X | X | X | F | 10 |
| 5.1.10 |
Participation in an external proficiency testing program |
X | X | X | C | 10 |
| 5.1.10.3 |
Proficiency testing results reviewed by the medical or laboratory director |
X | X | X | C | 10 |
| 5.2 | Outcome data | X | X | X | F | 10 |
| 5.2.4.1 |
Notification by patient-care service to issuing or processing facility of adverse events |
N/A | N/A | X | F | 10 |
| 5.3 |
Qualification of all materials used in the procurement, processing, and/or administration of cellular therapy products |
X | X | X | C | 10 |
| 5.3.2.1 | Quarantine of critical materials | X | X | X | C | 10 |
| 5.3.2.2 |
Complete records of the inspection of incoming materials that come into contact with the cellular therapy product or that directly affect the quality of the product |
N/A | N/A | X | C | 10 |
| 5.3.2.3 |
Identification of materials used on an emergency basis |
N/A | N/A | X | C | 10 |
| 5.3.4 | Inspection of in-house reagents | N/A | N/A | X | C | 10 |
| 5.3.5 |
Validation and monitoring of equipment, materials, and methods used in cleaning and sterilization of non-single-use materials |
X | X | X | C | 10 |
| 5.3.6 |
Use and identification of critical materials that come into contact with the patient or cellular therapy product |
X | X | X | F | 10 |
| 5.3.6.1 |
Package inserts, certificates of analysis, or any manufacturer’s documentation, including recall or defect notices, advisories, etc, for all critical materials used |
X | X | X | C | 10 |
| 5.4.2.1 |
Monitoring and review of the effectiveness of aseptic methods |
N/A | N/A | X | C | 10 |
| 5.4.3 |
Operational controls to prevent mix-up and contamination |
X | X | X | C | 10 |
| 5.5.1 |
Unique identification and traceability of cellular therapy products and samples from source to final disposition |
N/A | N/A | X | C | 10 |
| 5.6, #2, 3, 5 | Labeling controls | N/A | N/A | X | C | 10 |
| 5.6.1 | ISBT 128 implementation | N/A | N/A | X | C | 10 |
| 5.6.3 |
Verification of product packaging and labeling |
N/A | N/A | X | C | 10 |
| 5.7 | Transport of products | N/A | N/A | X | C | 10 |
| 5.7.2 |
Qualification of shipping containers and periodic requalification |
X | X | X | C | 10 |
| 5.7.3 |
Monitoring of temperature for noncryopreserved products |
N/A | N/A | X | F | 10 |
| 5.7.3.1 |
Continuous monitoring of temperature for cryopreserved products |
N/A | N/A | X | F | 10 |
| 5.7.6 |
Product acceptance and shipper temperature upon receipt |
N/A | N/A | X | C | 10 |
| 5.8 | Inspection and testing activities | X | X | X | C | 10 |
| 5.8.1 |
Inspection of incoming cells, tissues, and organs |
N/A | N/A | X | C | 10 |
| 5.8.2 |
Inspection and testing of products during processing |
N/A | N/A | X | C | 10 |
| 5.9.1 |
Storage area temperature and humidity |
X | X | X | C | 10 |
| 5.9.1.1 |
If cellular therapy products are stored in an open storage area, the ambient temperature recorded at least every 4 hours |
X | X | X | C | 10 |
| 5.9.3, 5.9.4 |
Monitoring of temperature and/or liquid nitrogen levels in storage devices and documentation of alarm activation |
X | X | X | C | 10 |
| 5.10 |
Determination of donor eligibility and verification that procurement criteria (eg, informed consent) have been met |
N/A | X | N/A | F | 10 |
| 5.10.2.2 |
Infectious disease testing of donors |
N/A | X | N/A | F | 10 |
| 5.10.2.3 | Cadaveric donor eligibility | N/A | X | N//A | F | 10 |
| 5.10.2.4 | Donor testing performed | N/A | X | N/A | F | 10 |
| 5.10.4 |
Review of donor screening and infectious disease testing record before international shipment or transport |
N/A | X | N/A | F | 10 |
| 5.10.5 |
Final determination of donor eligibility |
N/A | X | N/A | F | 10 |
| 5.10.6.2 |
Communication of abnormal results on medical history screening or testing that may affect the donor’s health |
N/A | X | N/A | F | 10 |
| 5.10.6.3 |
Communication of abnormal results on medical history screening or testing that may affect the recipient’s health or the therapeutic value of the cellular therapy product |
N/A | X | N/A | F | 10 |
| 5.10.6.4 | Ineligible donors | N/A | X | N/A | C | 10 |
| 5.10.7 | Products from ineligible donors | N/A | X | N/A | F | 10 |
| 5.10.8 |
Incomplete donor eligibility determination for donors not screened or tested |
N/A | X | N/A | F | 10 |
| 5.10.8.2 |
Physician notification of incomplete donor eligibility |
N/A | X | N/A | C | 10 |
| 5.11.2 |
Central venous access device placement by qualified individual or physician |
N/A | X | N/A | C | 10 |
| 5.11.3.1 |
Evaluation of allogeneic and autologous donors for the risk of hemoglobinopathy before the administration of a mobilizing agent |
N/A | X | N/A | C | 10 |
| 5.12.1 | Medical order for procurement | N/A | X | N/A | F | 10 |
| 5.12.2.2, 5.12.2.4 |
Final approval and documentation by the donor’s physician (or by a health-care professional, if appropriate) that the donor is able to proceed with donation in conformance with Reference Standard 5.10A, General Requirements for Cellular Therapy Product Donors |
N/A | X | N/A | F | 10 |
| 5.12.2.3 |
For donors of mobilized cells (apheresis), a complete blood count obtained within 24 hours before each procurement procedure; for marrow donors, a complete blood count obtained before procurement |
N/A | X | N/A | C | 10 |
| 5.12.4 |
Confirmation of donor identity, at the time of procurement, by two identifiers |
N/A | X | N/A | F | 10 |
| 5.12.5 |
Identification numbers and expiration dates of lot numbers of all disposables and additives used in procurement |
N/A | X | N/A | F | 10 |
| 5.12.5, 5.12.6 |
Complete procurement record; review of procurement record |
N/A | X | N/A | F | 10 |
| 5.13 | Definition of procurement goals | N/A | N/A | X | F | 10 |
| 5.15.1 |
Medical orders for processing, preservation, or storage |
X | X | X | F | 10 |
| 5.15.2 |
Complete processing record; verification that acceptable values or ranges for defined critical characteristics for each product were obtained |
N/A | N/A | X | F | 10 |
| 5.15.3 |
Determination of acceptable values or ranges |
N/A | N/A | X | C | 10 |
| 5.15.4 |
Procedures used to manage red cell antigen incompatibility |
N/A | N/A | X | F | 10 |
| 5.16 |
Product-specific specifications and acceptable storage conditions of noncryopreserved products |
N/A | N/A | X | C | 10 |
| 5.17.2.1.1 |
Segment identification by two individuals |
N/A | N/A | X | C | 10 |
| 5.17.3 |
Complete cryopreservation records |
N/A | N/A | X | F | 10 |
| 5.18 |
Stability program for each type of cellular therapy product and expiration dates |
X | X | X | C | 10 |
| 5.19 |
Disposition of products consistent with informed consent and laws and regulations |
X | X | X | F | 10 |
| 5.20.2, 5.20.3 |
Review of donation criteria, final processing criteria, and final product-specified requirements |
N/A | N/A | X | C | 10 |
| 5.20.2, 5.20.3 |
Review of donation criteria, final processing criteria, and final product-specified requirements |
N/A | N/A | X | F | 10 |
| 5.21 | Request for distribution | N/A | N/A | X | C | 10 |
| 5.22 | Product issue | N/A | N/A | X | F | 10 |
| 5.22.1 | Review of criteria for issue | N/A | N/A | X | F | 10 |
| 5.22.4 | Product return | N/A | N/A | X | F | 10 |
| 5.22.5 | Product reissue | N/A | N/A | X | F | 10 |
| 5.24 | Clinical care of the recipient | N/A | N/A | X | F | 10 |
| 5.24.1.2 | Medical orders for administration | X | X | X | F | 10 |
| 5.25 |
Preparation of the recipient for administration of the cellular therapy product |
N/A | N/A | X | F | 10 |
| 5.26.2 | Review of criteria for receipt | N/A | N/A | X | F | 10 |
| 5.27 |
Confirmation of identity of the product and the intended recipient, using at least two identifiers |
N/A | N/A | X | F | 10 |
| 5.27.3 |
Identification of adverse events occurring during the infusion of final cellular therapy products and communication to the issuing facility |
N/A | N/A | X | F | 10 |
| 5.27.4 | Records of administration | N/A | N/A | X | F | 10 |
| 5.27.5 |
Complete administration record and recipient records |
N/A | N/A | X | F | 10 |
| 6.1.2 |
Document control, including review and approval of all documents before use |
X | X | X | C | 10 |
| 6.1.3 |
Review and approval of changes to documents |
X | X | X | C | 10 |
| 6.1.4 |
List of all active policies, processes, procedures, labels, and forms |
X | X | X | C | 10 |
| 6.1.5 |
Biennial review of each policy, process, or procedure |
X | X | X | C | 10 |
| 6.1.6 |
Documents that are archived, destroyed, or made obsolete |
X | X | X | C | 10 |
| 6.2.5 | Record change | X | X | X | C | 10 |
| 6.2.7 |
Verification that copies of records contain the original content and are legible, complete, and accessible before the original records are destroyed |
X | X | X | C | 10 |
| 6.2.10 |
Review of records for accuracy, completeness, and compliance with applicable standards, laws, and regulations |
X | X | X | C | 10 |
| 6.3 | Electronic records | X | X | X | C | 10 |
| 6.3.1.1.1 |
Date and identity of person making change(s) to electronic records |
X | X | X | C | 10 |
| 7.1 | Deviations | X | X | X | F | 10 |
| 7.2 | Nonconforming products or services | X | X | X | F | 10 |
| 7.2.4 |
Nature of nonconformances discovered after release and subsequent actions taken, including acceptance for use |
X | X | X | F | 10 |
| 7.2.4.1 |
Disposition of the nonconforming product or service |
X | X | X | F | 10 |
| 7.2.5.3 |
Impact of nonconforming products on purity, potency, safety, or efficacy of the product |
X | X | X | F | 10 |
| 7.2.6.2 |
Authorized release of nonconforming products |
X | X | X | F | 10 |
| 7.3.3 |
Detection, reporting, and evaluation of procurement-related donor adverse events |
X | X | X | F | 10 |
| 7.3.4 |
Detection, reporting, evaluation, and treatment of administrationrelated recipient adverse events |
X | X | X | F | 10 |
| 7.3.5 |
Evaluation of reported adverse events |
X | X | X | F | 10 |
| 7.3.6.1 |
Evaluation and reporting of communicable diseases |
X | X | X | F | 10 |
| 8.1 | Internal assessments | X | X | X | C | 10 |
| 8.2 | External assessments | X | X | X | C | 10 |
| 8.3 |
Management of assessment results |
X | X | X | C | 10 |
| 8.5 | Monitoring of critical activities | X | X | X | C | 10 |
| 9.0 |
Implementation of changes to policies, processes, and procedures resulting from corrective and preventive action |
X | X | X | C | 10 |
| 9.1 | Corrective action | X | X | X | F | 10 |
| 9.2 | Preventive action | X | X | X | F | 10 |
| 10.1.3.1.1 | Alarm investigation | X | X | X | C | 10 |
| 10.1.4, #3 | Cleaning or sanitation processes | X | X | X | C | 10 |
| 10.1.4.1 | Environmental monitoring | X | X | X | C | 10 |
| 10.2 |
Monitoring of biological, chemical, and radiation safety |
X | X | X | C | 10 |
| 10.3 | Appropriate discard of products | X | X | X | C | 10 |
1Applicable federal, state, or local law may exceed this period.